Humer Kristian 4
4 · 4D Molecular Therapeutics, Inc. · Filed Dec 11, 2025
Insider Transaction Report
Form 4
Humer Kristian
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-12-09+480,000→ 480,000 totalExercise: $10.51Exp: 2035-12-08→ Common Stock (480,000 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the stock option vest on the first anniversary measured from November 17, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.